Critical Pharmaceuticals and The University of Nottingham to Develop Nano-Enabled Nasal Spray for Osteoporosis
Project to receive more than $800,000 US in funding for the collaboration
Story content courtesy of B3 Newswire, DE
Teriparatide, a drug used for the treatment of osteoporosis, currently needs to be injected every day. The consortium will expand on a recent discovery in nanotechnology to develop a nasal spray formulation of teriparatide that is easy to administer by patients and provides optimal drug plasma levels to enhance efficacy. The UK’s Technology Strategy Board and the Engineering and Physical Sciences Research Council (EPSRC) are supporting this project with grant funding as part of their investment in nanoscale technology-enabled solutions in healthcare. Critical Pharmaceuticals’ CriticalSorb™ nanotechnology believes it has a best in class absorption promoter that enables the nasal delivery of biological and challenging small molecule drugs.